HER2-Targeted Agents In Breast Cancer

HER2-targeted agents are highly effective in improving survival in HER2-positive patients.

Therefore, trastuzumab (+/- pertuzumab), both of which target HER2, are part of every regimen endorsed by NCCN for HER2-positive disease.

These are often combined with standard chemotherapy, composed of anthracyclines (such as doxorubicin) and/or taxanes (such as docetaxel and paclitaxel).

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. Available at http://www.nccn.org.

Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in her2 positive breast cancer. N Engl J Med. 2011;365:1273-1283.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s